Bioavailability increases by 75% when contents are taken without the capsule shell.

Renal dosing removed temporarily, refer to Renal Dosing Policy via Policy Finder on GHS Connect

12-19-2012 The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves, also known as mechanical prosthetic heart valves. A clinical trial in Europe (the RE-ALIGN trial)¹ was recently stopped because Pradaxa users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of the anticoagulant warfarin.

Guidelines for Use

Reversal of Anticoagulants

Angicoagulation Alerts Chart

Interruption for Colonoscopies, Dental Procedures, Surgery, etc.

Emergent Reversal

The Anticoagulation Management Program may be found by using the search function in Policies and Procedures.

The High Risk/High Alert Medication Policy may be found by using the search function in Policies and Procedures.

• Recent Citations via Medline (PubMed)
• FDA DRUG INFORMATION
• MICROMEDEX
• FDA Daily Med Package Inserts